沙雷肽酶 Serrapeptase × 骨關節炎

結論:證據支持

There is essentially no direct evidence for serrapeptase (serratiopeptidase) in osteoarthritis.

C 🟠 C 薄弱證據 已發布 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 🇹🇼 台灣在地警示

There is essentially no direct evidence for serrapeptase (serratiopeptidase) in osteoarthritis. The PubMed search (L2) found no dedicated serrapeptase-for-OA randomized controlled trial; the frequently cited Klein and Kullich (2000) knee-OA enzyme trial actually used Phlogenzym (a bromelain/trypsin/rutin combination), not serrapeptase, and is a miscitation that must not be counted. Examine has no osteoarthritis or joint-pain entry for serrapeptase at all (L1). The 2013 systematic review (PMID 23380245) graded the entire serratiopeptidase evidence base as methodologically poor and insufficient to support its use as an analgesic, and the agent's prescription-drug approval was withdrawn in Japan in 2011 for failing to beat placebo, with Taiwan's regulator likewise concluding insufficient efficacy and declining license renewal. No medical institution (Mayo, Cleveland, Harvard) or society (ACR, OARSI) addresses serrapeptase for osteoarthritis. With zero condition-specific trials and a parent evidence base judged poor by regulators and reviewers, the only honest grade is Unproven / Insufficient (U).

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.43
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 已發布
信心度
77%
證據方向大致一致
證據層級
E3
單篇高品質統合分析

各層「支持此療效」的程度

分數越低=該層越不支持
L11 AI 複核獨立判讀
0.20
L2 PubMed原始文獻
0.40
L3 機轉生理合理性
0.45
L1 Examine國際基準
0.50
L5 臨床機構權威立場
0.50
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.427
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Serratiopeptidase: a systematic review of the existing evidence
PMID: 23380245 2013 系統性回顧
結論:Identified 24 clinical efficacy studies and 11 RCTs across mixed indications (mainly ENT, dental, post-surgical). Concluded the existing scientific evidence for serratiopeptidase is insufficient to support its use as an analgesic and health supplement; most studies graded as poor methodology (small samples, poorly defined enrollment/outcomes, unclear statistics, short duration). No dedicated osteoarthritis or joint-pain trial identified.
🟠 品質有限 效應量:not estimable — evidence base too weak and heterogeneous to pool
前往 PubMed
Serratiopeptidase: Insights into the therapeutic applications
PMID: 33134103 2020 Other
結論:Reviews proposed anti-inflammatory, antiedemic and fibrinolytic activity. States robust clinical evidence is lacking and that data on antiatherosclerotic activity, safety, tolerability, efficacy and mechanism of action are still required. Notes the 2011 voluntary withdrawal of Danzen/Dasen serratiopeptidase tablets in Japan after failure to show efficacy superior to placebo. No osteoarthritis-specific efficacy data presented.
🟠 品質有限 效應量:not estimable
前往 PubMed

L4a US FDA
謹慎
Products may be legally marketed as dietary supplements if claims about diagnosis, cure, mitigation, treatment, or prevention are removed from promotional materials and the products otherwise comply with all applicable provisions of the Act and FDA regulations. 來源↗
L4b EU EFSA
反對
L4c UK NHS
反對
Serratiopeptidase is an unauthorised novel food, and it is illegal for businesses to sell serrapeptase as a food supplement for human consumption in the EU and UK because it is an unauthorised novel food. 來源↗
L4d TW TFDA / 衛福部
中性
適應症:手術後及外傷後之消炎、副鼻腔炎、膀胱炎、副睪丸炎、智齒周圍炎、齒槽膿瘍之消炎、支氣管炎。 來源↗
L4e WHO
未表態
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
未表態
— 本適應症無對應資料

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 極高
📍立場總覽

PTT、Dcard、Mobile01、痞客邦皆無「沙雷肽酶用於骨關節炎」的真實社群討論。台灣關節保健社群討論集中於葡萄糖胺(固力伸/骨營)、PRP 增生療法與玻尿酸注射;沙雷肽酶相關內容僅見於保健品廠商與健康媒體業配頁(iHerb 部落格、營養新知、盈康社、WEDAR),非匿名鄉民實測。屬冷門無在地討論主題,不杜撰社群心得。

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

強效沙雷肽酶Serrapeptase(延遲釋放)

代表來源 ↗
L10b · TFDA 法定身份 官方認定

以現在要求的臨床數據評估,並無足夠證據足以支持其療效

來源 ↗

  • 陸上運動與肌力訓練
  • 減重(過重者)
  • 局部或口服 NSAID
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 2 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v22 engine_version: v1.0 claim_id: CLM-COND-osteoarthritis-INT-serrapeptase-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-osteoarthritis-INT-serrapeptase-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "沙雷肽酶能改善骨關節炎",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}